JP2003530357A5 - - Google Patents

Download PDF

Info

Publication number
JP2003530357A5
JP2003530357A5 JP2001574143A JP2001574143A JP2003530357A5 JP 2003530357 A5 JP2003530357 A5 JP 2003530357A5 JP 2001574143 A JP2001574143 A JP 2001574143A JP 2001574143 A JP2001574143 A JP 2001574143A JP 2003530357 A5 JP2003530357 A5 JP 2003530357A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
antigen
antifungal agent
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001574143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530357A (ja
Filing date
Publication date
Priority claimed from GBGB0008305.5A external-priority patent/GB0008305D0/en
Application filed filed Critical
Publication of JP2003530357A publication Critical patent/JP2003530357A/ja
Publication of JP2003530357A5 publication Critical patent/JP2003530357A5/ja
Pending legal-status Critical Current

Links

JP2001574143A 2000-04-06 2001-03-20 抗hsp抗体と組み合わせたポリエンまたはβグルカンシンターゼインヒビター抗真菌薬での真菌感染症の治療 Pending JP2003530357A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections
GB0008305.5 2000-04-06
PCT/GB2001/001195 WO2001076627A1 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies

Publications (2)

Publication Number Publication Date
JP2003530357A JP2003530357A (ja) 2003-10-14
JP2003530357A5 true JP2003530357A5 (enExample) 2008-05-08

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001574143A Pending JP2003530357A (ja) 2000-04-06 2001-03-20 抗hsp抗体と組み合わせたポリエンまたはβグルカンシンターゼインヒビター抗真菌薬での真菌感染症の治療

Country Status (19)

Country Link
US (4) US20030180285A1 (enExample)
EP (4) EP1852128A1 (enExample)
JP (1) JP2003530357A (enExample)
CN (3) CN1420786A (enExample)
AT (1) ATE364396T1 (enExample)
AU (2) AU2001240890B2 (enExample)
BR (1) BR0109846A (enExample)
CA (1) CA2401836A1 (enExample)
CY (1) CY1106794T1 (enExample)
DE (1) DE60128893T2 (enExample)
DK (1) DK1267925T3 (enExample)
ES (1) ES2287105T3 (enExample)
GB (1) GB0008305D0 (enExample)
NO (1) NO20024815L (enExample)
NZ (1) NZ520899A (enExample)
PL (1) PL358394A1 (enExample)
PT (1) PT1267925E (enExample)
RU (1) RU2262952C2 (enExample)
WO (1) WO2001076627A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1457499A1 (en) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
SG153877A1 (en) * 2004-07-02 2009-07-29 Neutec Pharma Plc Treatment of cancer
KR20070050918A (ko) 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
CN101193862B (zh) * 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) * 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
WO2026133151A1 (en) * 2024-12-16 2026-06-25 Universita' Degli Studi Di Roma "Tor Vergata" Pharmaceutical composition containing trifarotene for use in the treatment of fungal infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Similar Documents

Publication Publication Date Title
US8236321B2 (en) Chemically programmable immunity
US10570193B2 (en) Binding moieties for biofilm remediation
RU2002129510A (ru) ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-HSP90-АНТИТЕЛАМИ
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US20140010885A1 (en) Self-assembling nanoparticle drug delivery system
RU2007119319A (ru) Наборы антигенов полипептида, угнетающего секрецию желудка (gip), и их применение
EP2298807A3 (en) Antibodies directed against amyloid-beta peptide and methods using same
NZ595386A (en) Peptides for treatment and diagnosis of autoimmune disease
DE69535360T2 (de) Synthetische peptide und impfstoffe welche diese beinhalten
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
WO2016154491A1 (en) Binding moieties for biofilm remediation
US20120053116A1 (en) Scytovirin domain 1 related polypeptides
WO2007145760A3 (en) Anthrax compositions and methods of use and production
JP2022520550A5 (enExample)
Hostetter An integrin-like protein in Candida albicans: implications for pathogenesis
US11707511B2 (en) Vaccine compositions and methods of using the same
JP2004533991A5 (enExample)
Kakeya et al. Concurrent subcutaneous candidal abscesses and pulmonary cryptococcosis in a patient with diabetes mellitus and a history of corticosteroid therapy
ATE373091T1 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
CA2259141A1 (en) Treatment and diagnosis of infections of gram positive cocci
CA2484719A1 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies, and methods of using scytovirins
RU2006141354A (ru) Лечение микозов
JP2004502782A5 (enExample)
JPWO2020250923A5 (enExample)
WO2000052053A1 (en) Antibodies against phosphomannan that are protective against candidiasis